Sugi Predict

Sugi Predict / Targets / B3GNT2

B3GNT2

N-acetyllactosaminide beta-1,3-N-acetylglucosaminyltransferase 2 · Q9NY97 · B3GNT2 on Sugi Atlas →

1,339 patent compounds predicted against B3GNT2, 564 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL27739914 SCHEMBL27739914 0.60 19/20
SCHEMBL25432383 SCHEMBL25432383 0.64 18/20
SCHEMBL30792666 SCHEMBL30792666 0.57 16/20
SCHEMBL30792648 SCHEMBL30792648 0.54 16/20
SCHEMBL640633 SCHEMBL640633 0.54 13/20
SCHEMBL32663049 SCHEMBL32663049 0.52 11/20
SCHEMBL32663100 SCHEMBL32663100 0.52 11/20
SCHEMBL32663104 SCHEMBL32663104 0.52 11/20
SCHEMBL28352929 SCHEMBL28352929 0.48 11/20
SCHEMBL28352930 SCHEMBL28352930 0.48 11/20
SCHEMBL639581 SCHEMBL639581 0.50 9/20
SCHEMBL30289054 SCHEMBL30289054 0.46 9/20
SCHEMBL2262647 SCHEMBL2262647 0.40 9/20
SCHEMBL6763505 SCHEMBL6763505 0.48 8/20
SCHEMBL10834119 SCHEMBL10834119 0.47 8/20
SCHEMBL32663068 SCHEMBL32663068 0.58 7/20
SCHEMBL20529180 SCHEMBL20529180 0.57 7/20
SCHEMBL27760417 SCHEMBL27760417 0.50 7/20
SCHEMBL21839375 SCHEMBL21839375 0.75 6/20
SCHEMBL319785 SCHEMBL319785 0.41 6/20

Clinical trials — most relevant to B3GNT2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Clinical Trials of N-acetyl Glucosamine Capsule for IBS-D Treatment PHASE3UNKNOWN
Oral N-acetylglucosamine in Crohn's Disease PHASE2NOT_YET_RECRUITING
Efficacy of Monosialotetrahexosylganglioside in the Prophylactic Treatment of Bortezomib-induced Peripheral Neuropathy PHASE2UNKNOWN
A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis PHASE1/PHASE2RECRUITING
Vaccine Treatment for Advanced Non-Small Cell Lung Cancer PHASE1/PHASE2COMPLETED
Multi-Center Study of ManNAc for GNE Myopathy PHASE2ACTIVE_NOT_RECRUITING
An Open Label Phase 2 Study of ManNAc in Subjects With GNE Myopathy PHASE2COMPLETED
The NADage Study: Nicotinamide Riboside Replenishment Therapy Against Functional Decline in Aging PHASE2RECRUITING
A Phase 1 Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ManNAc in Subjects With Primary Podocyte Diseases PHASE1COMPLETED
A Study of Safety, Tolerability, and Pk of rhMBL in Pediatric Hematology/Oncology Pts With Fever and Neutropenia PHASE1WITHDRAWN
N-Acetyl Glucosamine as Therapeutic Intervention for Coronavirus Disease-19 (COVID-19) PHASE1COMPLETED
Sialic Acid Supplementation in N-Acetylneuraminic Acid Synthase (NANS) Deficiency nanCOMPLETED
Biomarker for Mucolipidosis Disorder Type I, II, III, IV (BioML) nanWITHDRAWN
A Retrospective Study to Identify New Omics Biomarkers of Chronic/Persistent Low Back Pain nanCOMPLETED
Glycosylation in Patients With Galactosaemia nanCOMPLETED
The Natural History of Alpha-Mannosidosis nanCOMPLETED
NAG-excretion During Cardiopulmonary Bypass nanCOMPLETED
Institution of an Italian Multicenter Database of Patients Affected by Diseases of Phosphate Metabolism nanNOT_YET_RECRUITING
Evaluation of Blood Protein O-GlcNAcylation Levels in Children nanRECRUITING
Diagnostic Study of Combined Biomnarker Testing in Bronchoalveolar Lavage Samples of Immunocompromised Patients nanUNKNOWN
Diagnostic Accuracy of Pleural Effusion Aspergillosis Biomarker Testing nanUNKNOWN
BMN 110 US Expanded Access Program nanAPPROVED_FOR_MARKETING
Biomarker for Gangliosidosis: BioGM1/BioGM2 (BioGM1/GM2) nanWITHDRAWN
GNAO1 Natural History Study nanUNKNOWN
Histoblood Group Antigens as a Risk Factor of Asthma nanCOMPLETED
Using D-Galactose as a Food Supplement in Congenital Disorders of Glycosylation nanCOMPLETED
Evaluation of Intestinal Secretion of Antibodies and Auto-antibodies Associated With Crohn's Disease nanCOMPLETED
Natural History of Glycosphingolipid Storage Disorders and Glycoprotein Disorders nanRECRUITING
Pharmacodynamics and Tolerance of Nicotinamide Mononucleotide (NMN, 400mg/Day) in Healthy Adults nanCOMPLETED
Nicotinamide Riboside Clinical Trial for GWI nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a B3GNT2 binder may also engage these)

ProteinNameSimilarity
Q9Z222 — 0.997 Q9Z222 →
O54905 — 0.975 O54905 →
Q6NRQ1 — 0.973 Q6NRQ1 →
O43825 — 0.972 O43825 →
Q5R5Y3 — 0.972 Q5R5Y3 →
Q66H69 — 0.971 Q66H69 →
Q8K0J2 — 0.970 Q8K0J2 →
Q9YHB3 — 0.970 Q9YHB3 →
Q8NFL0 — 0.968 Q8NFL0 →
Q5M900 — 0.968 Q5M900 →
Q66PG2 — 0.966 Q66PG2 →
Q5DTK1 — 0.965 Q5DTK1 →
Q2HJ96 — 0.965 Q2HJ96 →
Q5NDE7 — 0.964 Q5NDE7 →
Q864U8 — 0.963 Q864U8 →
Q502B3 — 0.963 Q502B3 →
ENPP1 Ectonucleotide pyrophosphatase/phosphodiesterase family member 1 0.963 landscape →
Q4R4A8 — 0.963 Q4R4A8 →
Q66PG4 — 0.963 Q66PG4 →
Q864U6 — 0.962 Q864U6 →
P79949 — 0.961 P79949 →
MEP1A Meprin A subunit alpha 0.961 landscape →
Q7T3S5 — 0.961 Q7T3S5 →
Q8L7F9 — 0.961 Q8L7F9 →
Q66PG1 — 0.960 Q66PG1 →
Q66PG3 — 0.960 Q66PG3 →
Q9ASW1 — 0.960 Q9ASW1 →
Q920V1 — 0.960 Q920V1 →
Q08BL3 — 0.960 Q08BL3 →
Q9LV16 — 0.960 Q9LV16 →